GLP-1RAs and dual incretin therapies have redefined medical management of obesity, delivering average weight loss in the ~10–20% range and—critically—cardiovascular risk reduction in high-risk populations. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.